(Applicant?s Description) The H. Lee Moffitt Cancer Center requests renewal of its National Cancer Institute (NCI) Center Core Support Grant (CCSG) for years 4-8 and designation as a Comprehensive Cancer Center. The Center has continued its remarkable growth, nearly doubling both its NCI and total peer reviewed funding during the first two years of the CCSG. The Center has added nearly 50,000 sq ft of new research space and will add another 200,000 sq ft of new research space in 2003. All of the commitments to the growth of the Center and its scientific staff will allow it to achieve its sole mission of """"""""contributing to the prevention and cure of cancer."""""""" As one of only a handful of freestanding centers located on a university campus, the Moffitt Cancer Center enjoys the benefits of being freestanding within the intellectual arena of a university based matrix center. In addition, the Center benefits from extraordinary support from the State of Florida, the University of South Florida and its own Board of Directors. The Center, which brings together all clinical and research approaches to cancer at the University of South Florida under one management structure, seeks support for four scientific programs, 11 shared resources, seven staff investigators, developmental funds and administration. In 1997, the Cancer Center asked the site reviewers to recognize the Center?s potential to become a major NCI designated cancer center and contributor to the national cancer research program. The Moffitt Cancer Center has remained true to that commitment and seeks to expand upon it.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA076292-05S1
Application #
6652936
Study Section
Subcommittee G - Education (NCI)
Program Officer
Rosenfeld, Bobby
Project Start
1998-02-19
Project End
2006-01-31
Budget Start
2002-02-01
Budget End
2003-01-31
Support Year
5
Fiscal Year
2002
Total Cost
$105,624
Indirect Cost
Name
University of South Florida
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
City
Tampa
State
FL
Country
United States
Zip Code
33612
Schmit, Stephanie L; Edlund, Christopher K; Schumacher, Fredrick R et al. (2018) Novel Common Genetic Susceptibility Loci for Colorectal Cancer. J Natl Cancer Inst :
Ctortecka, Claudia; Palve, Vinayak; Kuenzi, Brent M et al. (2018) Functional Proteomics and Deep Network Interrogation Reveal a Complex Mechanism of Action of Midostaurin in Lung Cancer Cells. Mol Cell Proteomics 17:2434-2447
Ferreiro-Iglesias, Aida; Lesseur, Corina; McKay, James et al. (2018) Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity. Nat Commun 9:3927
Kang, Sokbom; Thompson, Zachary; McClung, E Claire et al. (2018) Gene Expression Signature-Based Prediction of Lymph Node Metastasis in Patients With Endometrioid Endometrial Cancer. Int J Gynecol Cancer 28:260-266
Kowalski, Allison; Striley, Catherine Woodstock; Varma, Deepthi Satheesa et al. (2018) Interactions between Alcohol Consumption and Adjuvant Hormone Therapy in Relation to Breast Cancer-Free Survival. J Breast Cancer 21:158-164
Konno, Hiroyasu; Yamauchi, Shota; Berglund, Anders et al. (2018) Suppression of STING signaling through epigenetic silencing and missense mutation impedes DNA damage mediated cytokine production. Oncogene 37:2037-2051
Gonzalez, Brian D; Hoogland, Aasha I; Kasting, Monica L et al. (2018) Psychosocial impact of BRCA testing in young Black breast cancer survivors. Psychooncology 27:2778-2785
Akuffo, Afua A; Alontaga, Aileen Y; Metcalf, Rainer et al. (2018) Ligand-mediated protein degradation reveals functional conservation among sequence variants of the CUL4-type E3 ligase substrate receptor cereblon. J Biol Chem 293:6187-6200
Mahajan, Nupam P; Coppola, Domenico; Kim, Jongphil et al. (2018) Blockade of ACK1/TNK2 To Squelch the Survival of Prostate Cancer Stem-like Cells. Sci Rep 8:1954
Rounbehler, Robert J; Berglund, Anders E; Gerke, Travis et al. (2018) Tristetraprolin Is a Prognostic Biomarker for Poor Outcomes among Patients with Low-Grade Prostate Cancer. Cancer Epidemiol Biomarkers Prev 27:1376-1383

Showing the most recent 10 out of 1254 publications